LACunar Intervention Trial-3 (LACI-3): Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke. LACI-3 is a research study testing whether two existing drugs — cilostazol and isosorbide mononitrate — can help protect the brain and prevent further strokes, cognitive decline, and mobility problems in people with lacunar stroke, a common form of stroke caused by cerebral small vessel disease. Although both drugs are already used for other conditions, this is the first trial targeting small blood vessel damage in the brain.To learn more about the LACI-3 Trial, visit the dedicated website: Visit the LACI-3 Trial website This article was published on 2024-08-27